Urologix (Urologix) Valuation Rank

View and export this data going back to 1996. Start your Free Trial

What is Urologix Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Urologix Valuation Rank Related Terms

Thank you for viewing the detailed overview of Urologix's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Urologix (Urologix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447

Website

http://www.urologix.com

Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.

Executives

Emery Sidney W Jr	director	C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler	director	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet	director, officer: CEO	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore	director
Guy C Jackson	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks	director	ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon	officer: Chief Technology Officer
Bobby Ivan Griffin	director	1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo	officer: VP, Product Dev. & Operations	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote	director	649 SUMMIT AVENUE, ST PAUL MN 55105